Diabetologia 47 , 20122021, doi: 10.1007/s00125-004-1570-9 (2004)
Heebll S, Risikesan J, Ringgaard S et al (2022) Impaired glucagon-mediated suppression of VLDL-triglyceride secretion in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD)
For example, the REWIND trial for dulaglutide and the SELECT trial for semaglutide (obesity patients) show statistically significant reductions in heart attack, stroke, or cardiovascular death ( [19] )
On the other hand, low portal insulin levels (e.g., during prolonged fasting) reduce hepatic GHR expression, thereby reducing IGF-1 levels and increasing GH concentrations by the lack of IGF-1 feedback on pituitary GH secretion (Fig
Long-Term Success With GLP-1 Medications GLP-1 medications are a toolnot a standalone solution
10.1111/j.1463-1326.2009.01167.x 53